By Colin Kellaher

 

Contract drug maker Catalent Inc. (CTLT) has agreed to buy Bristol-Myers Squibb Co.'s (BMY) oral solid, biologics and sterile product manufacturing and packaging plant in Anagni, Italy, for an undisclosed amount, the companies said Wednesday.

Catalent will continue to make Bristol-Myers' current product portfolio at the site, along with products for other customers, the companies said, adding that they expect to complete the transaction by the end of the year.

The manufacturing plant, with about 63,300 feet of floor space, sits on an 84-acre site roughly 60 miles southeast of Rome.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

June 19, 2019 09:23 ET (13:23 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Catalent (NYSE:CTLT)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Catalent Charts.
Catalent (NYSE:CTLT)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Catalent Charts.